Neurofibromatosis Type 1: A Mother’s Struggle Living with Thousands of Tumors
source: shutterstock.com

Neurofibromatosis Type 1: A Mother’s Struggle Living with Thousands of Tumors

According to a story from StokeonTrentLive, 34-year-old mother Rachel Potter is living with thousands of tumors thanks to a rare genetic disorder called neurofibromatosis type 1 (NF1). Though they aren't…

Continue Reading Neurofibromatosis Type 1: A Mother’s Struggle Living with Thousands of Tumors
STUDY: 33% of Adults with Severe Autoimmune Hemolytic Anemia Responded Well to Add-On IVIG
qimono / Pixabay

STUDY: 33% of Adults with Severe Autoimmune Hemolytic Anemia Responded Well to Add-On IVIG

Prednisone, oral steroids, intravenous hydrocortisone, and even blood transfusions are used to treat autoimmune hemolytic anemia (AIHA). AIHA comprises of warm AIHA, mixed AIHA, or cold agglutinin disease (CAD). Some…

Continue Reading STUDY: 33% of Adults with Severe Autoimmune Hemolytic Anemia Responded Well to Add-On IVIG
New Podcast Episode: Epilepsy and Unmet Need, feat. The LGS Foundation and Ovid Therapeutics
source: shutterstock.com

New Podcast Episode: Epilepsy and Unmet Need, feat. The LGS Foundation and Ovid Therapeutics

Patient Worthy's award-winning podcast "Wait, How Do You Spell That? A Rare Disease Podcast" is back with a new episode. This week, Colby is sitting down with Dr. Tracy Dixon-Salazar,…

Continue Reading New Podcast Episode: Epilepsy and Unmet Need, feat. The LGS Foundation and Ovid Therapeutics
Japanese Scientists Reversed Signs of Alzheimer’s by Restoring Synapse Function in Mouse Model
source: shutterstock.com

Japanese Scientists Reversed Signs of Alzheimer’s by Restoring Synapse Function in Mouse Model

A team of scientists from Japan appear to have pioneered a method for reversing synapse damage in an Alzheimer's disease mouse model. Although encouraging, the theory must be tested in…

Continue Reading Japanese Scientists Reversed Signs of Alzheimer’s by Restoring Synapse Function in Mouse Model
This Drug Could Prevent PAH in People with Scleroderma
source: shutterstock.com

This Drug Could Prevent PAH in People with Scleroderma

According to a story from Scleroderma News, findings from the recent Phase 2 EDITA clinical trial suggested that ambrisentan (marketed as Letairis), which is approved to treat pulmonary arterial hypertension…

Continue Reading This Drug Could Prevent PAH in People with Scleroderma
Rare Community Profiles: The Monster Inside: How a Boundary-Breaking Treatment Helped Sean in His Battle with von Hippel-Lindau Syndrome
source: pixabay.com

Rare Community Profiles: The Monster Inside: How a Boundary-Breaking Treatment Helped Sean in His Battle with von Hippel-Lindau Syndrome

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: The Monster Inside: How a Boundary-Breaking Treatment Helped Sean in His Battle with von Hippel-Lindau Syndrome
FDA’s Panel of Experts Vote 11-0 in Favor of Donanemab to Treat Alzheimer’s Disease
source: shutterstock.com

FDA’s Panel of Experts Vote 11-0 in Favor of Donanemab to Treat Alzheimer’s Disease

The idiom ‘third time’s a charm’ may have some significance in this instance. The panel that advises the FDA just voted unanimously in favor of Eli Lilly’s experimental drug, donanemab.…

Continue Reading FDA’s Panel of Experts Vote 11-0 in Favor of Donanemab to Treat Alzheimer’s Disease
Rare Community Profiles: Stigma Stops Anal Cancer Screenings, But Dr. Gary Bucher is Ready to Start Conversations on the Importance of Anal Health
Fotocitizen / Pixabay

Rare Community Profiles: Stigma Stops Anal Cancer Screenings, But Dr. Gary Bucher is Ready to Start Conversations on the Importance of Anal Health

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: Stigma Stops Anal Cancer Screenings, But Dr. Gary Bucher is Ready to Start Conversations on the Importance of Anal Health
Higher Sugar Intake Boosts Risk of Liver Fibrosis in Latino Teens
source: shutterstock.com

Higher Sugar Intake Boosts Risk of Liver Fibrosis in Latino Teens

Professor Michael Goran was referring to research data that was presented at the annual 2023 conference of the Hepatology, Gastroenterology, and Nutrition Society of North America when he stressed that…

Continue Reading Higher Sugar Intake Boosts Risk of Liver Fibrosis in Latino Teens
A Potential Methylmalonic Acidemia Therapy Will be Developed Under the FDA’s START Pilot Program
source: shutterstock.com

A Potential Methylmalonic Acidemia Therapy Will be Developed Under the FDA’s START Pilot Program

Rare diseases are challenging. Not just for those affected, but for researchers, physicians, and drug developers. Rare diseases may affect small populations. Many are poorly understood and lack adequate awareness.…

Continue Reading A Potential Methylmalonic Acidemia Therapy Will be Developed Under the FDA’s START Pilot Program
STUDY: Pitolisant Reduced Fatigue and Daytime Sleepiness in Adults with DM1
Source: https://unsplash.com/photos/ZHys6xN7sUE

STUDY: Pitolisant Reduced Fatigue and Daytime Sleepiness in Adults with DM1

An estimated 80% or more of people with myotonic dystrophy type 1 (DM1) struggle with severe fatigue and excessive daytime sleepiness (EDS). While most people consider myotonia (inability to contract…

Continue Reading STUDY: Pitolisant Reduced Fatigue and Daytime Sleepiness in Adults with DM1
Researchers Identify Underlying Disease Mechanism in RVCL
qimono / Pixabay

Researchers Identify Underlying Disease Mechanism in RVCL

Researchers have previously linked TREX1 gene mutations to the development of a rare inherited small vessel disease called retinal vasculopathy with cerebral leukoencephalopathy (RVCL). What researchers didn't know was why these genetic…

Continue Reading Researchers Identify Underlying Disease Mechanism in RVCL
Volunteers Needed for Alpers Syndrome Study
Source: pixabay.com

Volunteers Needed for Alpers Syndrome Study

Stemnovate is a biotechnology company working to transform the drug discovery landscape while improving diagnostics. Currently, the company hopes to develop a research platform for rare pediatric mitochondrial diseases such…

Continue Reading Volunteers Needed for Alpers Syndrome Study
Rare Community Profiles: The Only One Diagnosed in the US: Why Gabby is Starting Conversations on NLSD-M
source: pixabay.com

Rare Community Profiles: The Only One Diagnosed in the US: Why Gabby is Starting Conversations on NLSD-M

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.'…

Continue Reading Rare Community Profiles: The Only One Diagnosed in the US: Why Gabby is Starting Conversations on NLSD-M
Mirum Pharmaceuticals: Results Available from PBC and PSC Studies on Volixibat
source: shutterstock.com

Mirum Pharmaceuticals: Results Available from PBC and PSC Studies on Volixibat

Mirum Pharmaceuticals has long been a leader in the rare liver disease space, driving forward with a mission of empowering patients and families, and identifying novel therapeutic interventions to help…

Continue Reading Mirum Pharmaceuticals: Results Available from PBC and PSC Studies on Volixibat
Farxiga® has been FDA Approved to Treat Children and Adolescents in the U.S. for Type 2 Diabetes
source: shutterstock.com

Farxiga® has been FDA Approved to Treat Children and Adolescents in the U.S. for Type 2 Diabetes

Ruud Dobber, executive VP of biopharmaceuticals at AstraZeneca was quoted in a press release dated saying that type 2 diabetes is on the rise in adolescents and younger children with…

Continue Reading Farxiga® has been FDA Approved to Treat Children and Adolescents in the U.S. for Type 2 Diabetes